- Home
- PLUS vs IMCR Comparison
PLUS vs IMCR Comparison
Compare PLUS & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUS
- IMCR
- Stock Information
- Founded
- PLUS 1990
- IMCR 2008
- Country
- PLUS United States
- IMCR United Kingdom
- Employees
- PLUS N/A
- IMCR N/A
- Industry
- PLUS Retail: Computer Software & Peripheral Equipment
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLUS Technology
- IMCR Health Care
- Exchange
- PLUS Nasdaq
- IMCR Nasdaq
- Market Cap
- PLUS 1.7B
- IMCR 1.5B
- IPO Year
- PLUS 1996
- IMCR 2021
- Fundamental
- Price
- PLUS $72.46
- IMCR $33.02
- Analyst Decision
- PLUS
- IMCR Buy
- Analyst Count
- PLUS 0
- IMCR 10
- Target Price
- PLUS N/A
- IMCR $58.13
- AVG Volume (30 Days)
- PLUS 222.0K
- IMCR 444.9K
- Earning Date
- PLUS 08-05-2025
- IMCR 08-07-2025
- Dividend Yield
- PLUS N/A
- IMCR N/A
- EPS Growth
- PLUS N/A
- IMCR N/A
- EPS
- PLUS 4.05
- IMCR N/A
- Revenue
- PLUS $2,068,789,000.00
- IMCR $333,581,000.00
- Revenue This Year
- PLUS $3.88
- IMCR $26.82
- Revenue Next Year
- PLUS $2.84
- IMCR $8.15
- P/E Ratio
- PLUS $17.89
- IMCR N/A
- Revenue Growth
- PLUS N/A
- IMCR 25.75
- 52 Week Low
- PLUS $53.83
- IMCR $23.15
- 52 Week High
- PLUS $106.98
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- PLUS 57.62
- IMCR 51.47
- Support Level
- PLUS $70.16
- IMCR $30.76
- Resistance Level
- PLUS $75.80
- IMCR $33.95
- Average True Range (ATR)
- PLUS 2.07
- IMCR 1.39
- MACD
- PLUS -0.26
- IMCR -0.15
- Stochastic Oscillator
- PLUS 57.18
- IMCR 43.05
About PLUS ePlus inc.
ePlus Inc is a holding company. ePlus through its subsidiaries provides information technology solutions. The company's technology solutions enable organizations to optimize their IT environment and supply chain processes. It also provides consulting, professional and managed services, and complete lifecycle management services including flexible financing solutions. ePlus focuses on selling to medium and large enterprises in the United States and to customers in select international markets including the United Kingdom, the European Union, India, Singapore and Israel.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.